查看购物车
  • Traditional Chinese
  • English
  • Japanese
  • Korean
封面
市场调查报告书
商品编码
1405864

膀胱过动症治疗市场规模/份额/趋势分析报告：按类型、疾病类型、配销通路、地区、细分市场预测，2024-2030

Overactive Bladder Treatment Market Size, Share & Trends Analysis Report, By Type (Anticholinergics, Mirabegron, Neuromodulation, Botox), By Disease Type (Idiopathic, Neurogenic), By Distribution Channel, By Region, And Segment Forecasts, 2024 - 2030
出版日期: | 出版商: Grand View Research | 英文 100 Pages | 商品交期: 2-10个工作天内

价格

膀胱过动症治疗市场的成长与趋势：

根据 Grand View Research, Inc. 的最新报告，到 2030 年，全球膀胱过动症治疗市场规模预计将达到 52.5 亿美元，预测期内复合年增长率为 4.8%。

提高人们对膀胱过动症（OAB）疾病的认识以及增加研发投资以开发针对这种疾病的新製剂等因素预计将推动全球市场的发展。此外，由于对膀胱过动症药物和治疗方法的高需求而加剧的竞争以及大公司对药品製造的日益关注也是推动需求成长的重要因素。

人们对 OAB 和尿失禁的认识不断提高是推动市场成长的主要因素之一。该行业的主要企业已经采取了许多措施来提高人们对膀胱过动症症的认识。例如，2023 年 1 月，市场主要企业Urovant Sciences 与演员兼患者 Holly Robinson Peete 合作进行了宣传活动。此类倡议有助于提高对治疗方案的认识和了解，从而提高治疗方法的采用率。

此外，预计在预测期内增加对开发针对 OAB 的创新製剂和治疗方法的投资将推动成长。例如，2019 年 11 月，新兴企业EBT Medical, Inc. 获得了 1,000 万美元的 A 轮融资，用于开发一种非侵入性神经调节技术来治疗膀胱过动症。因此，专注于药物和治疗的开发和投资预计将推动地理扩张。

此外，行业参与企业正在采取各种策略，例如联盟和新产品发布，以保持在这个竞争激烈的市场中的地位。例如，2023年3月，杏林製药株式会社与住友製药株式会社合作，开始在台湾和新加坡、香港、印尼等亚洲国家开发、製造和商业化OAB治疗药物Vibegron和越南。这些领先公司之间的合作预计将改善每个国家获得药物和治疗方法的机会，并进一步推动未来几年的成长。

膀胱过动症治疗市场报告亮点

  • 米拉贝隆製剂将于 2023 年主导市场。这是由于米拉贝隆治疗 OAB 的采用率和处方率很高。
  • 依疾病类型划分，特发性膀胱过动症由于其盛行率较高，对 2023 年行业销售额的贡献最大。
  • 在配销通路上，零售药局占据市场主导地位。高收益成长归因于提供 OAB 治疗的老牌零售药局的存在和高患者适用性。
  • 由于辉瑞 (Pfizer, Inc.)、艾伯维 (AbbVie, Inc.) 和 Viatris, Inc. 等主要企业在该地区的存在，北美将在 2023 年膀胱过动症治疗市场。

目录

第一章调查方法与范围

第 2 章执行摘要

第三章市场变数、趋势和范围

  • 市场体系展望
    • 母市场展望
    • 相关/附随市场展望
  • 市场动态
    • 市场驱动因素分析
    • 市场抑制因素分析
  • 产业分析工具
    • 波特五力分析
    • PESTEL分析
    • COVID-19感染疾病的影响分析

第 4 章业务分析的类型

  • 膀胱过动症治疗市场：类型变异分析
  • 抗胆碱能药物
  • 米拉贝隆
  • 肉毒桿菌
  • 神经调节
  • 其他的

第五章病种业务分析

  • 膀胱过动症治疗市场：疾病类型变异分析
  • 特发性膀胱过动症
  • 神经源性膀胱过动症

第六章配销通路业务分析

  • 膀胱过动症治疗市场：配销通路波动分析
  • 医院药房
  • 零售药房
  • 其他的

第七章 区域业务分析

  • 2023 年及 2030 年膀胱过动症治疗市场占有率（按地区）
  • 北美洲
    • 2018-2030年北美膀胱过动症治疗市场
    • 美国
    • 加拿大
  • 欧洲
    • 2018-2030年欧洲膀胱过动症治疗市场
    • 英国
    • 德国
    • 法国
    • 义大利
    • 西班牙
    • 丹麦
    • 瑞典
    • 挪威
  • 亚太地区
    • 亚太地区膀胱过动症治疗市场，2018-2030
    • 日本
    • 中国
    • 印度
    • 澳洲
    • 泰国
    • 韩国
  • 拉丁美洲
    • 拉丁美洲膀胱过动症治疗市场，2018-2030
    • 巴西
    • 墨西哥
    • 阿根廷
  • 中东/非洲
    • MEA膀胱过动症治疗市场，2018-2030
    • 南非
    • 沙乌地阿拉伯
    • 阿拉伯聯合大公国
    • 科威特

第八章竞争形势

  • 公司分类
  • 策略规划
  • 2023 年公司市场占有率分析
  • 公司简介/名单
    • Pfizer, Inc
    • AbbVie Inc.
    • Astellas Pharma Inc.
    • Medtronic
    • Sumitomo Pharma America, Inc.（Urovant Sciences.）
    • Viatris Inc.
    • Teva Pharmaceutical Industries Ltd.
    • Hisamitsu Pharmaceutical Co., Inc.
    • Macleods Pharmaceuticals Ltd.
    • Endo International plc
Product Code: GVR-4-68040-168-0

Overactive Bladder Treatment Market Growth & Trends:

The global overactive bladder treatment market size is expected to reach USD 5.25 billion by 2030, and is estimated to register a CAGR of 4.8% over the forecast period, according to a new report by Grand View Research, Inc. Factors such as the growing awareness about the overactive bladder (OAB) condition, along with rising R&D investments to develop novel formulations for this disease, are projected to drive the global market. In addition, rising competition owing to high demand for OAB medications and treatments and rising emphasis of major players to manufacture drugs is another vital factor propelling the demand forward.

Rising awareness about OAB and urinary incontinence among the population is one of the major factors bolstering the growth of the market. Various key players operating in the industry undertake numerous initiatives to raise awareness about the overactive bladder condition. For instance, in January 2023, Urovant Sciences, a key player operating in the market, collaborated with actress and patient Holly Robinson Peete under a campaign to bring awareness to OAB. Such initiatives help increase awareness and knowledge about the treatment options thereby increasing treatment adoption.

Moreover, increasing investments to develop innovative formulations and treatments targeting OAB are anticipated to fuel growth over the forecast period. For instance, in November 2019, EBT Medical, Inc., a startup, received funding of USD 10 million in series A for developing noninvasive neuromodulation technology to treat overactive bladder. Thus, developments and investments focusing on medications and treatments are anticipated to fuel the geographic expansion.

Furthermore, industry participants are undertaking various strategies like collaborations and new product launches to maintain their position in this competitive market. For instance, in March 2023, KYORIN Pharmaceutical Co., Ltd. collaborated with Sumitomo Pharma Co., Ltd. to develop, manufacture, and commercialize Vibegron for OAB in Taiwan and other Asian Countries like Singapore, Hong Kong, Indonesia, and Vietnam. Such collaborations among major players are expected to increase the accessibility of drugs and treatments across the countries, which can further propel growth in the coming years.

Overactive Bladder Treatment Market Report Highlights:

  • Mirabegron drug dominated the market in 2023 with a which can be attributed to the high adoption and prescription rate of Mirabegron for treating OAB
  • Among disease-type segments, the idiopathic overactive bladder segment was the largest revenue contributor for the industry in 2023 due to its high prevalence rate
  • In the distribution channel segment, the retail pharmacies dominated the market. The higher revenue growth is attributed to the presence of established retail pharmacies offering OAB drugs and its better patient compatibility
  • North America dominated the market for overactive bladder treatment in 2023 owing to the presence of key players such as Pfizer, Inc., AbbVie, Inc., and Viatris, Inc. across the region

Table of Contents

Chapter 1. Methodology and Scope

  • 1.1. Segment Definitions
    • 1.1.1. Product Segment
    • 1.1.2. Strength Segment
    • 1.1.3. Distribution Channel Segment
  • 1.2. Regional Scope
  • 1.3. Estimates and Forecast Timeline
  • 1.4. Objectives
    • 1.4.1. Objective - 1
    • 1.4.2. Objective - 2
    • 1.4.3. Objective - 3
  • 1.5. Research Methodology
  • 1.6. Information Procurement
    • 1.6.1. Purchased Database
    • 1.6.2. Gvr's Internal Database
    • 1.6.3. Secondary Sources
    • 1.6.4. Primary Research
  • 1.7. Information Or Data Analysis
    • 1.7.1. Data Analysis Models
  • 1.8. Market Formulation & Validation
  • 1.9. Model Details
    • 1.9.1. Commodity Flow Analysis
  • 1.10. List of Secondary Sources
  • 1.11. List of Abbreviations
  • 1.12. Research Assumptions

Chapter 2. Executive Summary

  • 2.1. Market Snapshot
  • 2.2. Segment Snapshot
  • 2.3. Competitive Landscape Snapshot

Chapter 3. Market Variables, Trends, & Scope

  • 3.1. Market Lineage Outlook
    • 3.1.1. Parent Market Outlook
    • 3.1.2. Related/Ancillary Market Outlook
  • 3.2. Market Dynamics
    • 3.2.1. Market Driver Analysis
      • 3.2.1.1. Increasing prevalence of target diseases
      • 3.2.1.2. Rising R&D investments for introducing new treatments
      • 3.2.1.3. Growing awareness about the condition
    • 3.2.2. Market Restraint Analysis
      • 3.2.2.1. Adverse effects associated with medications and treatment.
      • 3.2.2.2. Increasing product recalls
  • 3.3. Industry Analysis Tools
    • 3.3.1. Porter's Five Forces Analysis
    • 3.3.2. PESTEL Analysis
    • 3.3.3. COVID-19 Impact Analysis

Chapter 4. Type Business Analysis

  • 4.1. Overactive Bladder Treatment Market: Type Movement Analysis
  • 4.2. Anticholinergics
    • 4.2.1. Anticholinergics Market, 2018 - 2030 (USD Million)
  • 4.3. Mirabegron
    • 4.3.1. Mirabegron Market, 2018 - 2030 (USD Million)
  • 4.4. Botox
    • 4.4.1. Botox Market, 2018 - 2030 (USD Million)
  • 4.5. Neuromodulation
    • 4.5.1. Neuromodulation Market, 2018 - 2030 (USD Million)
  • 4.6. Others
    • 4.6.1. Other Types Market, 2018 - 2030 (USD Million)

Chapter 5. Disease Type Business Analysis

  • 5.1. Overactive Bladder Treatment Market: Disease Type Movement Analysis
  • 5.2. Idiopathic Overactive Bladder
    • 5.2.1. Idiopathic Overactive Bladder Market, 2018 - 2030 (USD Million)
  • 5.3. Neurogenic Overactive Bladder
    • 5.3.1. Neurogenic Overactive Bladder Market, 2018 - 2030 (USD Million)

Chapter 6. Distribution Channel Business Analysis

  • 6.1. Overactive Bladder Treatment Market: Distribution Channel Movement Analysis
  • 6.2. Hospital Pharmacies
    • 6.2.1. Hospital Pharmacies Market, 2018 - 2030 (USD Million)
  • 6.3. Retail Pharmacies
    • 6.3.1. Retail Pharmacies Market, 2018 - 2030 (USD Million)
  • 6.4. Others
    • 6.4.1. Others Market, 2018 - 2030 (USD Million)

Chapter 7. Regional Business Analysis

  • 7.1. Overactive Bladder Treatment Market Share By Region, 2023 & 2030
  • 7.2. North America
    • 7.2.1. North America Overactive Bladder Treatment Market, 2018 - 2030 (USD Million)
    • 7.2.2. U.S.
      • 7.2.2.1. Key Country Dynamics
      • 7.2.2.2. Competitive Scenario
      • 7.2.2.3. Regulatory Framework
      • 7.2.2.4. Reimbursement Scenario
      • 7.2.2.5. U.S. Overactive Bladder Treatment Market, 2018 - 2030 (USD Million)
    • 7.2.3. Canada
      • 7.2.3.1. Key Country Dynamics
      • 7.2.3.2. Competitive Scenario
      • 7.2.3.3. Regulatory Framework
      • 7.2.3.4. Reimbursement Scenario
      • 7.2.3.5. Canada Overactive Bladder Treatment Market, 2018 - 2030 (USD Million)
  • 7.3. Europe
    • 7.3.1. Europe Overactive Bladder Treatment Market, 2018 - 2030 (USD Million)
    • 7.3.2. UK
      • 7.3.2.1. Key Country Dynamics
      • 7.3.2.2. Competitive Scenario
      • 7.3.2.3. Regulatory Framework
      • 7.3.2.4. Reimbursement Scenario
      • 7.3.2.5. UK Overactive Bladder Treatment Market, 2018 - 2030 (USD Million)
    • 7.3.3. Germany
      • 7.3.3.1. Key Country Dynamics
      • 7.3.3.2. Competitive Scenario
      • 7.3.3.3. Regulatory Framework
      • 7.3.3.4. Reimbursement Scenario
      • 7.3.3.5. Germany Overactive Bladder Treatment Market, 2018 - 2030 (USD Million)
    • 7.3.4. France
      • 7.3.4.1. Key Country Dynamics
      • 7.3.4.2. Competitive Scenario
      • 7.3.4.3. Regulatory Framework
      • 7.3.4.4. Reimbursement Scenario
      • 7.3.4.5. France Overactive Bladder Treatment Market, 2018 - 2030 (USD Million)
    • 7.3.5. Italy
      • 7.3.5.1. Key Country Dynamics
      • 7.3.5.2. Competitive Scenario
      • 7.3.5.3. Regulatory Framework
      • 7.3.5.4. Reimbursement Scenario
      • 7.3.5.5. Italy Overactive Bladder Treatment Market, 2018 - 2030 (USD Million)
    • 7.3.6. Spain
      • 7.3.6.1. Key Country Dynamics
      • 7.3.6.2. Competitive Scenario
      • 7.3.6.3. Regulatory Framework
      • 7.3.6.4. Reimbursement Scenario
      • 7.3.6.5. Spain Overactive Bladder Treatment Market, 2018 - 2030 (USD Million)
    • 7.3.7. Denmark
      • 7.3.7.1. Key Country Dynamics
      • 7.3.7.2. Competitive Scenario
      • 7.3.7.3. Regulatory Framework
      • 7.3.7.4. Reimbursement Scenario
      • 7.3.7.5. Denmark Overactive Bladder Treatment Market, 2018 - 2030 (USD Million)
    • 7.3.8. Sweden
      • 7.3.8.1. Key Country Dynamics
      • 7.3.8.2. Competitive Scenario
      • 7.3.8.3. Regulatory Framework
      • 7.3.8.4. Reimbursement Scenario
      • 7.3.8.5. Sweden Overactive Bladder Treatment Market, 2018 - 2030 (USD Million)
    • 7.3.9. Norway
      • 7.3.9.1. Key Country Dynamics
      • 7.3.9.2. Competitive Scenario
      • 7.3.9.3. Regulatory Framework
      • 7.3.9.4. Reimbursement Scenario
      • 7.3.9.5. Norway Overactive Bladder Treatment Market, 2018 - 2030 (USD Million)
  • 7.4. Asia Pacific
    • 7.4.1. Asia Pacific Overactive Bladder Treatment Market, 2018 - 2030 (USD Million)
    • 7.4.2. Japan
      • 7.4.2.1. Key Country Dynamics
      • 7.4.2.2. Competitive Scenario
      • 7.4.2.3. Regulatory Framework
      • 7.4.2.4. Reimbursement Scenario
      • 7.4.2.5. Japan Overactive Bladder Treatment Market, 2018 - 2030 (USD Million)
    • 7.4.3. China
      • 7.4.3.1. Key Country Dynamics
      • 7.4.3.2. Competitive Scenario
      • 7.4.3.3. Regulatory Framework
      • 7.4.3.4. Reimbursement Scenario
      • 7.4.3.5. China Overactive Bladder Treatment Market, 2018 - 2030 (USD Million)
    • 7.4.4. India
      • 7.4.4.1. Key Country Dynamics
      • 7.4.4.2. Competitive Scenario
      • 7.4.4.3. Regulatory Framework
      • 7.4.4.4. Reimbursement Scenario
      • 7.4.4.5. India Overactive Bladder Treatment Market, 2018 - 2030 (USD Million)
    • 7.4.5. Australia
      • 7.4.5.1. Key Country Dynamics
      • 7.4.5.2. Competitive Scenario
      • 7.4.5.3. Regulatory Framework
      • 7.4.5.4. Reimbursement Scenario
      • 7.4.5.5. Australia Overactive Bladder Treatment Market, 2018 - 2030 (USD Million)
    • 7.4.6. Thailand
      • 7.4.6.1. Key Country Dynamics
      • 7.4.6.2. Competitive Scenario
      • 7.4.6.3. Regulatory Framework
      • 7.4.6.4. Reimbursement Scenario
      • 7.4.6.5. Thailand Overactive Bladder Treatment Market, 2018 - 2030 (USD Million)
    • 7.4.7. South Korea
      • 7.4.7.1. Key Country Dynamics
      • 7.4.7.2. Competitive Scenario
      • 7.4.7.3. Regulatory Framework
      • 7.4.7.4. Reimbursement Scenario
      • 7.4.7.5. South Korea Overactive Bladder Treatment Market, 2018 - 2030 (USD Million)
  • 7.5. Latin America
    • 7.5.1. Latin America Overactive Bladder Treatment Market, 2018 - 2030 (USD Million)
    • 7.5.2. Brazil
      • 7.5.2.1. Key Country Dynamics
      • 7.5.2.2. Competitive Scenario
      • 7.5.2.3. Regulatory Framework
      • 7.5.2.4. Reimbursement Scenario
      • 7.5.2.5. Brazil Overactive Bladder Treatment Market, 2018 - 2030 (USD Million)
    • 7.5.3. Mexico
      • 7.5.3.1. Key Country Dynamics
      • 7.5.3.2. Competitive Scenario
      • 7.5.3.3. Regulatory Framework
      • 7.5.3.4. Reimbursement Scenario
      • 7.5.3.5. Mexico Overactive Bladder Treatment Market, 2018 - 2030 (USD Million)
    • 7.5.4. Argentina
      • 7.5.4.1. Key Country Dynamics
      • 7.5.4.2. Competitive Scenario
      • 7.5.4.3. Regulatory Framework
      • 7.5.4.4. Reimbursement Scenario
      • 7.5.4.5. Argentina Overactive Bladder Treatment Market, 2018 - 2030 (USD Million)
  • 7.6. MEA
    • 7.6.1. MEA Overactive Bladder Treatment Market, 2018 - 2030 (USD Million)
    • 7.6.2. South Africa
      • 7.6.2.1. Key Country Dynamics
      • 7.6.2.2. Competitive Scenario
      • 7.6.2.3. Regulatory Framework
      • 7.6.2.4. Reimbursement Scenario
      • 7.6.2.5. South Africa Overactive Bladder Treatment Market, 2018 - 2030 (USD Million)
    • 7.6.3. Saudi Arabia
      • 7.6.3.1. Key Country Dynamics
      • 7.6.3.2. Competitive Scenario
      • 7.6.3.3. Regulatory Framework
      • 7.6.3.4. Reimbursement Scenario
      • 7.6.3.5. Saudi Arabia Overactive Bladder Treatment Market, 2018 - 2030 (USD Million)
    • 7.6.4. UAE
      • 7.6.4.1. Key Country Dynamics
      • 7.6.4.2. Competitive Scenario
      • 7.6.4.3. Regulatory Framework
      • 7.6.4.4. Reimbursement Scenario
      • 7.6.4.5. UAE Overactive Bladder Treatment Market, 2018 - 2030 (USD Million)
    • 7.6.5. Kuwait
      • 7.6.5.1. Key Country Dynamics
      • 7.6.5.2. Competitive Scenario
      • 7.6.5.3. Regulatory Framework
      • 7.6.5.4. Reimbursement Scenario
      • 7.6.5.5. Kuwait Overactive Bladder Treatment Market, 2018 - 2030 (USD Million)

Chapter 8. Competitive Landscape

  • 8.1. Company Categorization
  • 8.2. Strategy Mapping
  • 8.3. Company Market Share Analysis, 2023
  • 8.4. Company Profiles/Listing
    • 8.4.1. Pfizer, Inc
      • 8.4.1.1. Overview
      • 8.4.1.2. Financial Performance (Net Revenue/Sales/EBITDA/Gross Profit)
      • 8.4.1.3. Product Benchmarking
      • 8.4.1.4. Strategic Initiatives
    • 8.4.2. AbbVie Inc.
      • 8.4.2.1. Overview
      • 8.4.2.2. Financial Performance (Net Revenue/Sales/EBITDA/Gross Profit)
      • 8.4.2.3. Product Benchmarking
      • 8.4.2.4. Strategic Initiatives
    • 8.4.3. Astellas Pharma Inc.
      • 8.4.3.1. Overview
      • 8.4.3.2. Financial Performance (Net Revenue/Sales/EBITDA/Gross Profit)
      • 8.4.3.3. Product Benchmarking
      • 8.4.3.4. Strategic Initiatives
    • 8.4.4. Medtronic
      • 8.4.4.1. Overview
      • 8.4.4.2. Financial Performance (Net Revenue/Sales/EBITDA/Gross Profit)
      • 8.4.4.3. Product Benchmarking
      • 8.4.4.4. Strategic Initiatives
    • 8.4.5. Sumitomo Pharma America, Inc.( Urovant Sciences.)
      • 8.4.5.1. Overview
      • 8.4.5.2. Financial Performance (Net Revenue/Sales/EBITDA/Gross Profit)
      • 8.4.5.3. Product Benchmarking
      • 8.4.5.4. Strategic Initiatives
    • 8.4.6. Viatris Inc.
      • 8.4.6.1. Overview
      • 8.4.6.2. Financial Performance (Net Revenue/Sales/EBITDA/Gross Profit)
      • 8.4.6.3. Product Benchmarking
      • 8.4.6.4. Strategic Initiatives
    • 8.4.7. Teva Pharmaceutical Industries Ltd.
      • 8.4.7.1. Overview
      • 8.4.7.2. Financial Performance (Net Revenue/Sales/EBITDA/Gross Profit)
      • 8.4.7.3. Product Benchmarking
      • 8.4.7.4. Strategic Initiatives
    • 8.4.8. Hisamitsu Pharmaceutical Co., Inc.
      • 8.4.8.1. Overview
      • 8.4.8.2. Financial Performance (Net Revenue/Sales/EBITDA/Gross Profit)
      • 8.4.8.3. Product Benchmarking
      • 8.4.8.4. Strategic Initiatives
    • 8.4.9. Macleods Pharmaceuticals Ltd.
      • 8.4.9.1. Overview
      • 8.4.9.2. Financial Performance (Net Revenue/Sales/EBITDA/Gross Profit)
      • 8.4.9.3. Product Benchmarking
      • 8.4.9.4. Strategic Initiatives
    • 8.4.10. Endo International plc
      • 8.4.10.1. Overview
      • 8.4.10.2. Financial Performance (Net Revenue/Sales/EBITDA/Gross Profit)
      • 8.4.10.3. Product Benchmarking
      • 8.4.10.4. Strategic Initiatives

List of Tables

  • TABLE 1 List of Secondary Sources
  • TABLE 2 List of Abbreviations
  • TABLE 3 Global Overactive Bladder Treatment Market, By Type, 2018 - 2030 (USD Million)
  • TABLE 4 Global Overactive Bladder Treatment Market, By Disease Type, 2018 - 2030 (USD Million)
  • TABLE 5 Global Overactive Bladder Treatment Market, By Distribution Channel, 2018 - 2030 (USD Million)
  • TABLE 6 Global Overactive Bladder Treatment Market, By Region, 2018 - 2030 (USD Million)
  • TABLE 7 North America Overactive Bladder Treatment Market, By Country, 2018 - 2030 (USD Million)
  • TABLE 8 North America Overactive Bladder Treatment Market, By Type, 2018 - 2030 (USD Million)
  • TABLE 9 North America Overactive Bladder Treatment Market, By Disease Type, 2018 - 2030 (USD Million)
  • TABLE 10 North America Overactive Bladder Treatment Market, By Distribution Channel, 2018 - 2030 (USD Million)
  • TABLE 11 U.S. Overactive Bladder Treatment Market, By Type, 2018 - 2030 (USD Million)
  • TABLE 12 U.S. Overactive Bladder Treatment Market, By Disease Type, 2018 - 2030 (USD Million)
  • TABLE 13 U.S. Overactive Bladder Treatment Market, By Distribution Channel, 2018 - 2030 (USD Million)
  • TABLE 14 Canada Overactive Bladder Treatment Market, By Type, 2018 - 2030 (USD Million)
  • TABLE 15 Canada Overactive Bladder Treatment Market, By Disease Type, 2018 - 2030 (USD Million)
  • TABLE 16 Canada Overactive Bladder Treatment Market, By Distribution Channel, 2018 - 2030 (USD Million)
  • TABLE 17 Europe Overactive Bladder Treatment Market, By Country, 2018 - 2030 (USD Million)
  • TABLE 18 Europe Overactive Bladder Treatment Market, By Type, 2018 - 2030 (USD Million)
  • TABLE 19 Europe Overactive Bladder Treatment Market, By Disease Type, 2018 - 2030 (USD Million)
  • TABLE 20 Europe Overactive Bladder Treatment Market, By Distribution Channel, 2018 - 2030 (USD Million)
  • TABLE 21 UK Overactive Bladder Treatment Market, By Type, 2018 - 2030 (USD Million)
  • TABLE 22 UK Overactive Bladder Treatment Market, By Disease Type, 2018 - 2030 (USD Million)
  • TABLE 23 UK Overactive Bladder Treatment Market, By Distribution Channel, 2018 - 2030 (USD Million)
  • TABLE 24 Germany Overactive Bladder Treatment Market, By Type, 2018 - 2030 (USD Million)
  • TABLE 25 Germany Overactive Bladder Treatment Market, By Disease Type, 2018 - 2030 (USD Million)
  • TABLE 26 Germany Overactive Bladder Treatment Market, By Distribution Channel, 2018 - 2030 (USD Million)
  • TABLE 27 France Overactive Bladder Treatment Market, By Type, 2018 - 2030 (USD Million)
  • TABLE 28 France Overactive Bladder Treatment Market, By Disease Type, 2018 - 2030 (USD Million)
  • TABLE 29 France Overactive Bladder Treatment Market, By Distribution Channel, 2018 - 2030 (USD Million)
  • TABLE 30 Spain Overactive Bladder Treatment Market, By Type, 2018 - 2030 (USD Million)
  • TABLE 31 Spain Overactive Bladder Treatment Market, By Disease Type, 2018 - 2030 (USD Million)
  • TABLE 32 Spain Overactive Bladder Treatment Market, By Distribution Channel, 2018 - 2030 (USD Million)
  • TABLE 33 Italy Overactive Bladder Treatment Market, By Type, 2018 - 2030 (USD Million)
  • TABLE 34 Italy Overactive Bladder Treatment Market, By Disease Type, 2018 - 2030 (USD Million)
  • TABLE 35 Italy Overactive Bladder Treatment Market, By Distribution Channel, 2018 - 2030 (USD Million)
  • TABLE 36 Denmark Overactive Bladder Treatment Market, By Type, 2018 - 2030 (USD Million)
  • TABLE 37 Denmark Overactive Bladder Treatment Market, By Disease Type, 2018 - 2030 (USD Million)
  • TABLE 38 Denmark Overactive Bladder Treatment Market, By Distribution Channel, 2018 - 2030 (USD Million)
  • TABLE 39 Norway Overactive Bladder Treatment Market, By Type, 2018 - 2030 (USD Million)
  • TABLE 40 Norway Overactive Bladder Treatment Market, By Disease Type, 2018 - 2030 (USD Million)
  • TABLE 41 Norway Overactive Bladder Treatment Market, By Distribution Channel, 2018 - 2030 (USD Million)
  • TABLE 42 Sweden Overactive Bladder Treatment Market, By Type, 2018 - 2030 (USD Million)
  • TABLE 43 Sweden Overactive Bladder Treatment Market, By Disease Type, 2018 - 2030 (USD Million)
  • TABLE 44 Sweden Overactive Bladder Treatment Market, By Distribution Channel, 2018 - 2030 (USD Million)
  • TABLE 45 Asia Pacific Overactive Bladder Treatment Market, By Country, 2018 - 2030 (USD Million)
  • TABLE 46 Asia Pacific Overactive Bladder Treatment Market, By Type, 2018 - 2030 (USD Million)
  • TABLE 47 Asia Pacific Overactive Bladder Treatment Market, By Disease Type, 2018 - 2030 (USD Million)
  • TABLE 48 Asia Pacific Overactive Bladder Treatment Market, By Distribution Channel, 2018 - 2030 (USD Million)
  • TABLE 49 China Overactive Bladder Treatment Market, By Type, 2018 - 2030 (USD Million)
  • TABLE 50 China Overactive Bladder Treatment Market, By Disease Type, 2018 - 2030 (USD Million)
  • TABLE 51 China Overactive Bladder Treatment Market, By Distribution Channel, 2018 - 2030 (USD Million)
  • TABLE 52 Japan Overactive Bladder Treatment Market, By Type, 2018 - 2030 (USD Million)
  • TABLE 53 Japan Overactive Bladder Treatment Market, By Disease Type, 2018 - 2030 (USD Million)
  • TABLE 54 Japan Overactive Bladder Treatment Market, By Distribution Channel, 2018 - 2030 (USD Million)
  • TABLE 55 India Overactive Bladder Treatment Market, By Type, 2018 - 2030 (USD Million)
  • TABLE 56 India Overactive Bladder Treatment Market, By Disease Type, 2018 - 2030 (USD Million)
  • TABLE 57 India Overactive Bladder Treatment Market, By Distribution Channel, 2018 - 2030 (USD Million)
  • TABLE 58 South Korea Overactive Bladder Treatment Market, By Type, 2018 - 2030 (USD Million)
  • TABLE 59 South Korea Overactive Bladder Treatment Market, By Disease Type, 2018 - 2030 (USD Million)
  • TABLE 60 South Korea Overactive Bladder Treatment Market, By Distribution Channel, 2018 - 2030 (USD Million)
  • TABLE 61 Australia Overactive Bladder Treatment Market, By Type, 2018 - 2030 (USD Million)
  • TABLE 62 Australia Overactive Bladder Treatment Market, By Disease Type, 2018 - 2030 (USD Million)
  • TABLE 63 Australia Overactive Bladder Treatment Market, By Distribution Channel, 2018 - 2030 (USD Million)
  • TABLE 64 Thailand Overactive Bladder Treatment Market, By Type, 2018 - 2030 (USD Million)
  • TABLE 65 Thailand Overactive Bladder Treatment Market, By Disease Type, 2018 - 2030 (USD Million)
  • TABLE 66 Thailand Overactive Bladder Treatment Market, By Distribution Channel, 2018 - 2030 (USD Million)
  • TABLE 67 Latin America Overactive Bladder Treatment Market, By Country, 2018 - 2030 (USD Million)
  • TABLE 68 Latin America Overactive Bladder Treatment Market, By Type, 2018 - 2030 (USD Million)
  • TABLE 69 Latin America Overactive Bladder Treatment Market, By Disease Type, 2018 - 2030 (USD Million)
  • TABLE 70 Latin America Overactive Bladder Treatment Market, By Distribution Channel, 2018 - 2030 (USD Million)
  • TABLE 71 Brazil Overactive Bladder Treatment Market, By Type, 2018 - 2030 (USD Million)
  • TABLE 72 Brazil Overactive Bladder Treatment Market, By Disease Type, 2018 - 2030 (USD Million)
  • TABLE 73 Brazil Overactive Bladder Treatment Market, By Distribution Channel, 2018 - 2030 (USD Million)
  • TABLE 74 Mexico Overactive Bladder Treatment Market, By Type, 2018 - 2030 (USD Million)
  • TABLE 75 Mexico Overactive Bladder Treatment Market, By Disease Type, 2018 - 2030 (USD Million)
  • TABLE 76 Mexico Overactive Bladder Treatment Market, By Distribution Channel, 2018 - 2030 (USD Million)
  • TABLE 77 Argentina Overactive Bladder Treatment Market, By Type, 2018 - 2030 (USD Million),
  • TABLE 78 Argentina Overactive Bladder Treatment Market, By Disease Type, 2018 - 2030 (USD Million)
  • TABLE 79 Argentina Overactive Bladder Treatment Market, By Distribution Channel, 2018 - 2030 (USD Million)
  • TABLE 80 MEA Overactive Bladder Treatment Market, By Country, 2018 - 2030 (USD Million)
  • TABLE 81 MEA Overactive Bladder Treatment Market, By Type, 2018 - 2030 (USD Million)
  • TABLE 82 MEA Overactive Bladder Treatment Market, By Disease Type, 2018 - 2030 (USD Million)
  • TABLE 83 MEA Overactive Bladder Treatment Market, By Distribution Channel, 2018 - 2030 (USD Million)
  • TABLE 84 South Africa Overactive Bladder Treatment Market, By Type, 2018 - 2030 (USD Million)
  • TABLE 85 South Africa Overactive Bladder Treatment Market, By Disease Type, 2018 - 2030 (USD Million)
  • TABLE 86 South Africa Overactive Bladder Treatment Market, By Distribution Channel, 2018 - 2030 (USD Million)
  • TABLE 87 UAE Overactive Bladder Treatment Market, By Type, 2018 - 2030 (USD Million)
  • TABLE 88 UAE Overactive Bladder Treatment Market, By Disease Type, 2018 - 2030 (USD Million)
  • TABLE 89 UAE Overactive Bladder Treatment Market, By Distribution Channel, 2018 - 2030 (USD Million)
  • TABLE 90 Saudi Arabia Overactive Bladder Treatment Market, By Type, 2018 - 2030 (USD Million),
  • TABLE 91 Saudi Arabia Overactive Bladder Treatment Market, By Disease Type, 2018 - 2030 (USD Million)
  • TABLE 92 Saudi Arabia Overactive Bladder Treatment Market, By Distribution Channel, 2018 - 2030 (USD Million)
  • TABLE 93 Kuwait Overactive Bladder Treatment Market, By Type, 2018 - 2030 (USD Million)
  • TABLE 94 Kuwait Overactive Bladder Treatment Market, By Disease Type, 2018 - 2030 (USD Million)
  • TABLE 95 Kuwait Overactive Bladder Treatment Market, By Distribution Channel, 2018 - 2030 (USD Million)

List of Figures

  • Fig. 1 Market research process
  • Fig. 2 Information procurement
  • Fig. 3 Primary research pattern
  • Fig. 4 Market research approaches
  • Fig. 5 Value chain-based sizing & forecasting
  • Fig. 6 Market formulation & validation
  • Fig. 7 Overactive bladder treatment market segmentation
  • Fig. 8 Market snapshot, 2023
  • Fig. 9 Market trends & outlook
  • Fig. 10 Market driver relevance analysis (current & future impact)
  • Fig. 11 Market restraint relevance analysis (current & future impact)
  • Fig. 12 PESTEL analysis
  • Fig. 13 Porter's five forces analysis
  • Fig. 14 Global overactive bladder treatment market: Type outlook and key takeaways
  • Fig. 15 Global overactive bladder treatment market: Type movement analysis
  • Fig. 16 Global overactive bladder treatment market, for anticholinergics, 2018 - 2030 (USD Million)
  • Fig. 17 Global overactive bladder treatment market, for mirabegron, 2018 - 2030 (USD Million)
  • Fig. 18 Global overactive bladder treatment market, for Botox, 2018 - 2030 (USD Million)
  • Fig. 19 Global overactive bladder treatment market, for neuromodulation, 2018 - 2030 (USD Million)
  • Fig. 20 Global overactive bladder treatment market, for other types, 2018 - 2030 (USD Million)
  • Fig. 21 Global overactive bladder treatment market: Disease type outlook and key takeaways
  • Fig. 22 Global overactive bladder treatment market: Disease type movement analysis
  • Fig. 23 Global overactive bladder treatment market, for idiopathic overactive bladder, 2018 - 2030 (USD Million)
  • Fig. 24 Global overactive bladder treatment market, for neurogenic overactive bladder, 2018 - 2030 (USD Million)
  • Fig. 25 Global overactive bladder treatment market: Distribution channel outlook and key takeaways
  • Fig. 26 Global overactive bladder treatment market: Distribution channel movement analysis
  • Fig. 27 Global overactive bladder treatment market, for hospital pharmacy, 2018 - 2030 (USD Million)
  • Fig. 28 Global overactive bladder treatment market, for retail pharmacy, 2018 - 2030 (USD Million)
  • Fig. 29 Global overactive bladder treatment market, for others, 2018 - 2030 (USD Million)
  • Fig. 30 Regional marketplace: Key takeaways
  • Fig. 31 Regional outlook, 2022 & 2030
  • Fig. 32 Global overactive bladder treatment market: Region movement analysis
  • Fig. 33 North America overactive bladder treatment market, 2018 - 2030 (USD Million)
  • Fig. 34 U.S overactive bladder treatment market, 2018 - 2030 (USD Million)
  • Fig. 35 Canada overactive bladder treatment market, 2018 - 2030 (USD Million)
  • Fig. 36 Europe overactive bladder treatment market, 2018 - 2030 (USD Million)
  • Fig. 37 Germany overactive bladder treatment market, 2018 - 2030 (USD Million)
  • Fig. 38 U.K overactive bladder treatment market, 2018 - 2030 (USD Million)
  • Fig. 39 France overactive bladder treatment market, 2018 - 2030 (USD Million)
  • Fig. 40 Italy overactive bladder treatment market, 2018 - 2030 (USD Million)
  • Fig. 41 Spain overactive bladder treatment market, 2018 - 2030 (USD Million)
  • Fig. 42 Denmark overactive bladder treatment market, 2018 - 2030 (USD Million)
  • Fig. 43 Sweden overactive bladder treatment market, 2018 - 2030 (USD Million)
  • Fig. 44 Norway overactive bladder treatment market, 2018 - 2030 (USD Million)
  • Fig. 45 Asia Pacific overactive bladder treatment market, 2018 - 2030 (USD Million)
  • Fig. 46 Japan overactive bladder treatment market, 2018 - 2030 (USD Million)
  • Fig. 47 China overactive bladder treatment market, 2018 - 2030 (USD Million)
  • Fig. 48 India overactive bladder treatment market, 2018 - 2030 (USD Million)
  • Fig. 49 Australia overactive bladder treatment market, 2018 - 2030 (USD Million)
  • Fig. 50 South Korea overactive bladder treatment market, 2018 - 2030 (USD Million)
  • Fig. 51 Thailand overactive bladder treatment market, 2018 - 2030 (USD Million)
  • Fig. 52 Latin America overactive bladder treatment market, 2018 - 2030 (USD Million)
  • Fig. 53 Brazil overactive bladder treatment market, 2018 - 2030 (USD Million)
  • Fig. 54 Mexico overactive bladder treatment market, 2018 - 2030 (USD Million)
  • Fig. 55 Argentina overactive bladder treatment market, 2018 - 2030 (USD Million)
  • Fig. 56 Middle East and Africa overactive bladder treatment market, 2018 - 2030 (USD Million)
  • Fig. 57 South Africa overactive bladder treatment market, 2018 - 2030 (USD Million)
  • Fig. 58 Saudi Arabia overactive bladder treatment market, 2018 - 2030 (USD Million)
  • Fig. 59 UAE overactive bladder treatment market, 2018 - 2030 (USD Million)
  • Fig. 60 Kuwait overactive bladder treatment market, 2018 - 2030 (USD Million)